Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2022.058 | Decolonization of carbapenemase-producing Enterobacteriaceae through modulation of the gut microbiota and its resistome |
Prof. IP Margaret 葉碧瑤 |
| 2023.122 | A Belt and Road platform to track and tackle MRSA disease and carriage, elucidating their antimicrobial and biocide resistance, genetic diversity and transmission dynamics between humans, animals and the environment | Prof. IP Margaret |
| 2020.561 | A retrospective review of pneumococcal disease and other respiratory infection in Hong Kong hospitals |
Prof. IP Margaret 葉碧瑤 |
| 2008.030 | Factors Affecting Clinical Outcomes of Vancomyic Therapy for Methicillin-Resistant Staphylococcus Aureus Bactgeraemia | Dr Ip Margaret |
| 2020.007 | One Health approach to Track and Target Antimicrobial Resistance (TnT-AMR) |
Prof. IP Margaret 葉碧瑤 |
| 2018.261 | Isolation of CD34 stem cells from cord blood |
Prof. IP Margaret 叶碧瑶 |
| 2019.545 | Study for Monitoring Antimicrobial Resistance Trends (SMART) | Prof. IP Margaret |
| 2019.657 | Burden of Streptococcus agalactiae (GBS) disease in Hong Kong |
Prof. IP Margaret 葉碧瑤 |
| 2018.509 | A review on infections and colonization of Streptococcus agalactiae in Hong Kong, 2007-2021 | Prof. IP Margaret |
| 2019.013 | Surveillance of bacterial pathogens by whole-genome sequencing |
Prof. IP Margaret 葉碧瑤 |
| 2018.116 | Modulation of gut microbiota with probiotics: a pilot study |
Prof. IP Margaret 葉碧瑤 |
| 2018.628 | Resistome of gut microbiota and modulation in healthy Hong Kong population |
Prof. IP Margaret 葉碧瑤 |
| 2017.230 | Dissecting human and animal Streptococcus agalactiae (Group B streptococcus) and its resistance determinants through territory-wide sampling | Prof. IP Margaret |
| 2017.448 | A review on Serotypes and In-vitro Antibiotic Susceptibilities of Streptococcus pneumoniae from Hospitalized Adult Patients in a Hong Kong Hospital, 2015 - 2016. | Prof. IP Margaret |
| 2016.228 | Antibiotic Susceptibility testing of Temocillin and other agents against Enterobacteriaceae in Hong Kong. |
Prof IP Margaret 葉碧瑤 |
| 2015.519 | A review on Serotypes and In-vitro Antibiotic Susceptibilities of Streptococcus pneumoniae from Hospitalized Adult Patients in a Hong Kong Hospital, 2012 - 2014. |
Prof. IP Margaret 葉碧瑤 |
| 2014.306 | Combating Vancomycin-Resistant Enterococci (VRE) with antibiotics with active ingredients from Traditional Chinese Medicine (TCM) | Prof. IP Margaret |
| 2016.043 | Epidemiology and Detection of Carbapenemase-Producing Enterobacteriaceae (CPE) in Hong Kong hospitals |
Prof. IP Margaret 葉碧瑤 |
| 2017.152 | Whole Genome Sequencing-based characterization of Carbapenem-resistant Enterobacteriaceae in Hong Kong | Prof. IP Margaret |
| 2014.403 | Impact of macrolide non susceptibility in Mycoplasma pneumoniae on childhood respiratory diseases | Prof Ip Margaret |
| 2013.452 | The Evaluation of Computer Aided Pathology Diagnosis system for Tuberculosis Sputum Smear. | Prof. Ip Margaret |
| 2026.297 | Virulence determinants of ST6011 for escalated invasive pneumococcal diseases (IPDs) caused by Streptococcus pneumoniae serotype 3 in Hong Kong | Prof. Ip Margaret |
| 2010.305 | Evaluation of a nurse-led Comprehensive Child Development Service Program for high risk pregnant women in Hong Kong | Ms Ip Lai Sheung |
| 2008.494 | Compare the Clinical Outcomes of Non-operative Versus Operative Treatment in Mason Type II Radial Head Fracture, Restrospective Study | DR IP Kai Yuen |
| 2014.625 | The prevalence and risk factors associated with the use of Potentially Inappropriate Medication in Old Age Homes and Prince of Wales Hospital - a retrospective cohort study | Student Ip Kai Cheung |
| 2024.329 | Mindfulness Intervention for Reducing Stress and Anxiety in Postnatal Women: A Six-Week Program | Dr. IP KA HIM |
| 2024.209 | Molecular Characterization of CDKL5 Deficiency Disorders (CDD) with Human Brain Samples | Prof. IP Jacque Pak Kan |
| 2022.290 | A Fifteen-year Retrospective Review on Livedoid Vasculopathy in a Tertiary Centre | Dr. IP Edric Chi Ching |
| 2021.028 | A pilot randomized controlled trial of integrative Motivational Interviewing and Contingency Management program (MICM) for dual-diagnosed patients to enhance psychiatric medication adherence |
Mr. IP Chi Kin 葉志堅 |
| 2025.470 | Developing and Evaluating the Effects of a Virtual AI-De-escalation Education Programme on Confidence and Knowledge on Managing Aggressive Behaviour, patients' restraint rate and staff wellbeing: A Pilot Cluster Randomised Controlled Trial in Psychiatric Nursing Care |
Dr Ip Chi Kin 葉志堅 |
| 2025.881 | The use of accelerated protocol of intermittent Theta Burst Stimulation on the Craving for Hypnotic abusers (TBC-H): A double-blinded randomized controlled trial |
Dr. Ip Chi Kin 葉志堅 |
| 2025.709 | Acceptance and Commitment Therapy-based lifestyle counselling programme on physical activity in people with recent-onset psychosis: A randomised controlled trial | Dr. IP CHI KIN |
| 2025.718 | The use of accelerated protocol of intermittent Theta Burst Stimulation on the Craving and sleep for Hypnotic abusers (TBC-H): A pilot randomized controlled trial |
Dr. IP Chi Kin 葉志堅 |
| 2017.381 | The feasibility study over the outcomes of substance abusers in residential detox centers when compared with video medical consultation verus face-to-face consultation |
Mr. IP Chi Kin 葉志堅 |
| 2026.692 | A Pilot Cluster Randomized Controlled Trial of Dialectical Behaviour Therapy Skills Training (DBT-ST) for Chinese Psychiatric Inpatients with Personality Disorders (PD) to Reduce Self-Harm and Disturbing Behaviours |
Dr. Ip Chi Kin 葉志堅 |
| 2026.470 | Identification of hidden substance users: a data-driven approach |
Dr. Ip Chi Kin 葉志堅 |
| 2026.468 | Understanding the reasons and perspectives regarding hidden substance use: a focus group approach |
Dr. Ip Chi Kin 葉志堅 |
| 2026.263 | VR-AI Enhanced Anger Management For Patients with Severe Mental Illness: A Pilot Randomized Controlled Trial |
Dr. Ip Chi Kin 葉志堅 |
| 2026.244 | The use of accelerated protocol of intermittent Theta Burst Stimulation on the Craving for Stimulant abusers (TBC-S): A pilot double-blinded randomised controlled trial |
Dr. Ip Chi Kin 葉志堅 |
| 2026.697 | A Pilot Randomised Controlled Trial of Nurse-facilitated Bright Light Therapy for Improving Sleep Quality and Quantity in Adults with Non-Alcoholic Substance Use Disorder |
Dr. Ip Chi Kin 葉志堅 |
| 2020.383 | Effect of Acceptance and Commitment Therapy-based lifestyle counselling programme for people with early psychosis on physical activity: a pilot randomized controlled trial |
Mr. IP Chi Kin 葉志堅 |
| 2021.627 | Comparative efficacy and safety of treatments in Intracerebral Bleeding during Direct Oral Anticoagulant Usage – a population-based study |
Dr. IP Bonaventure Yiu Ming 葉耀明 |
| 2022.414 | Effective Translation of Endovascular Thrombectomy Trials into Real-world Practice in the Asia-Pacific: a multicenter, prospective registry (ENDURE-APAC) |
Dr. IP Bonaventure Yiu Ming 葉耀明 |
| 2023.340 | Prognostication of Intracerebral hemorrhage – a population-based study | Dr. IP Bonaventure Yiu Ming |
| 2022.352 | Prevalence and Etiologies of Intracranial Stenosis in Patients with Antiphospholipid Syndrome: a cross sectional study |
Dr. IP Bonaventure Yiu Ming 葉耀明 |
| 2023.295 | A Real-life study of Anti-CGRP medication in Asian Patients with migraine (REAP) | Dr. IP Bonaventure Yiu Ming |
| 2023.367 | A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack | Dr. IP Bonaventure Yiu Ming |
| 2022.241 | Brain Health in Oral Anticoagulant Recipients | Dr. IP Bonaventure Yiu Ming |
| 2021.349 | The Effect of Medication Prescription on First-ever Ischemic strokes - a territory-wide observational study |
Dr. IP Bonaventure Yiu Ming 葉耀明 |
| 2022.639 | Epidemiological Update on Migraine in Hong Kong |
Dr. IP Bonaventure Yiu Ming 葉耀明 |
Page 178 of 289.

